L3VLUP
ProSign in

BMRN · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BMRNVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BMRN
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterBMRNVRTX
Q3 202012 holders, $3.0bn31 holders, $21.9bn
Q4 202012 holders, $3.7bn30 holders, $18.4bn
Q1 202110 holders, $3.1bn31 holders, $15.4bn
Q2 202111 holders, $3.4bn30 holders, $12.7bn
Q3 202114 holders, $3.0bn35 holders, $10.1bn
Q4 202114 holders, $3.4bn28 holders, $12.4bn
Q1 202219 holders, $3.0bn23 holders, $16.1bn
Q2 202221 holders, $2.9bn25 holders, $18.1bn
Q3 202225 holders, $3.1bn22 holders, $18.4bn
Q4 202226 holders, $4.0bn28 holders, $18.4bn
Q1 202320 holders, $3.3bn26 holders, $21.4bn
Q2 202318 holders, $2.9bn27 holders, $24.7bn
Q3 202318 holders, $2.9bn33 holders, $24.3bn
Q4 202322 holders, $4.1bn32 holders, $28.6bn
Q1 202419 holders, $3.6bn31 holders, $29.8bn
Q2 202416 holders, $3.3bn29 holders, $33.4bn
Q3 202416 holders, $3.0bn27 holders, $33.5bn
Q4 202414 holders, $3.0bn26 holders, $28.5bn
Q1 202516 holders, $3.3bn21 holders, $35.4bn
Q2 202516 holders, $2.5bn21 holders, $32.3bn
Q3 202516 holders, $2.3bn22 holders, $25.9bn
Q4 202521 holders, $2.4bn26 holders, $31.8bn
Q1 202615 holders, $2.6bn25 holders, $31.8bn
Q2 202612 holders, $2.2bn26 holders, $34.6bn
BMRN

Biomarin Pharmaceutical Inc

Holders
21
Reported value
$2.4bn
Buyers
24
Sellers
19

Breadth +5 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$31.8bn
Buyers
19
Sellers
20

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BMRN (11)

AQR Capital Management LLC, Caxton Associates LLP, Dodge & Cox, ExodusPoint Capital Management LP, Freestone Grove Partners LP, Moore Capital Management LP, Schonfeld Strategic Advisors LLC, Steadfast Capital Management LP, Viking Global Investors LP, Voloridge Investment Management LLC, Walleye Capital LLC

Only VRTX (16)

AllianceBernstein LP, ARK Investment Management LLC, Baillie Gifford & Co, Balyasny Asset Management LLC, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →